Complicated Urinary Tract InfectionPhase 2NCT05826990
A Study to Investigate PK, Safety, Tolerability of Cefepime-enmetazobactam in Pediatric Participants With cUTI
A Phase 2 study testing cefepime and enmetazobactam combination in people with Complicated Urinary Tract Infection, run by Orchid Pharma Europe GmbH at 8 sites in 6 countries.
Trial summary
This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI. Read more about this study
- Who is it for?
- Ages Up to 18 years
- Conditions the study is for
- Complicated Urinary Tract Infection
- What is being tested?
- cefepime and enmetazobactam combination
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 8 sitesin 6 countries
- Study dates
- 11 Sep 2023to 21 May 2029
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Who may be able to join
- Participant must be from birth to <18 years of age. Participants up to 2 months must have been born at term or preterm with a gestational age ≥32 weeks.
- Written informed consent from parent(s) or other legally acceptable representative(s), and informed assent from participant (if age appropriate according to local regulations).
- If female and has reached menarche, or has reached Tanner stage 3 development, (even if not having reached menarche) the participant is authorized to participate in this clinical study if the following criteria are met:
- Participant has a negative urine and/or serum human chorionic gonadotropin test at screening visit. As serum tests may miss an early pregnancy, relevant menstrual history, and sexual history, including methods of contraception, should be considered
- Participant agrees to avoid conception from the time of screening until 7 days after receipt of study intervention and agrees not to attempt pregnancy from the time of screening until 7 days after EOT with study intervention, and participant agrees to follow guidelines received regarding continuation of abstinence, initiation of abstinence or about allowed contraception, and
- Participant reports sexual abstinence for the prior 3 months or reported the use of at least 1 of the acceptable methods of contraception, including an intrauterine device (with copper banded coil), levonorgestrel intrauterine system or regular medroxyprogesterone injections, or participant agrees to initiate sexual abstinence from the time of screening until 7 days after end of treatment (EOT) with study intervention.
Show all 39Show fewer
- Participant has a clinically suspected and/or bacteriologically documented complicated urinary tract infection (cUTI) or acute pyelonephritis judged by the investigator to require the participant to be hospitalized for treatment with intravenous (i.v.) therapy.
- The causative pathogen is confirmed or suspected to be susceptible to cefepime-enmetazobactam.
- Participant has pyuria, defined as dipstick analysis positive for leukocyte esterase OR:
- If ≥1 year of age: White blood cell (WBC) count >10 cells/µL in unspun urine or ≥10 cells/high power field in spun urine.
- If <1 year of age: WBC count >5 cells/µL in unspun urine or ≥5 cells/high power field in spun urine.
- Participant demonstrates clinical signs and/or symptoms of either acute pyelonephritis or cUTI at the Screening Visit, as defined by the following criteria:
- For pyelonephritis, participants must have at least 2 of the following new or worsening signs and/or symptoms: i. If 0 to <2 years of age:
- Fever (as defined by the investigator)
- Failure to thrive
- Recent weight loss
- Irritability
- Poor feeding
- Lack of normal level of activity
- Abdominal tenderness on physical examination
- Vomiting ii. If 2 to <18 years of age:
- Fever (as defined by the investigator)
- Dysuria
- Urinary urgency
- Urinary frequency
- New-onset urinary incontinence
- Suprapubic pain, flank pain, or abdominal pain
- Suprapubic tenderness or CVA tenderness on physical examination
- Nausea or vomiting OR
- For cUTI, participants must have at least 2 of the new or worsening signs and/or symptoms listed above AND must have at least 1 of the following complicating factors:
- Obstructive uropathy
- Congenital, functional, or anatomic abnormality of the urogenital tract
- Temporary indwelling urinary catheter
- Bladder instrumentation within <24 hours
- Recurrent UTI (≥2 events within a 12-month period)
- Have a baseline urine culture specimen obtained within 48 hrs prior to the first dose of the study intervention. (Participants may be enrolled in this study and start i.v. study intervention therapy before the Investigator knows the results of the baseline urine culture in the event the causative pathogen is suspected to be susceptible to cefepime-enmetazobactam).
- Specimen is to be obtained by suprapubic aspiration, clean intermittent urethral catheterization, indwelling urethral catheter, or mid- stream clean catch.
- Likely to survive the current illness or hospitalization.
- Sufficient intravascular access (peripheral or central) to receive study intervention
Who cannot join
- History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to cefepime, any cephalosporin, penicillins, β-lactamase inhibitors (e.g., tazobactam, sulbactam, or clavulanic acid), or other β-lactam agents.
- Previous enrolment in this study, or in another interventional study ≤30 days before i.v. administration of study intervention.
- Concurrent infection requiring systemic antibiotics in addition to the i.v. study intervention therapy at the time of first study intervention administration.
- Receipt of systemic antibiotics within 24 hours before obtaining the study qualifying pre-treatment baseline urine sample and before study intervention therapy. Exceptions are:
- Receipt up to 24 hours of short-acting antibacterial agent with a daily dose not completed. (Refer protocol ► Section 10.5, Appendix 5 for the list of allowed and disallowed antibiotics).
- Patients who received prior antimicrobial therapy for the current cUTI/AP, and 1) in the Investigator's opinion, failed that prior antibiotic therapy (i.e., presented with worsening signs and symptoms), AND 2) were documented that the pathogen is non-susceptible to the prior antibiotic therapy.
Show all 21Show fewer
- Patients who have received antimicrobial prophylaxis for recurrent cUTI and then presented signs and symptoms consistent with an active new cUTI or AP.
- A permanent indwelling bladder catheter or instrumentation including nephrostomy or current urinary catheter or anticipation of urinary catheter placement that would not be removed during the course of i.v. study intervention therapy administration.
- Participant has suspected or known complete obstruction of any portion of the urinary tract, perinephric abscess, or ileal loops.
- Participant has trauma to the pelvis or urinary tract.
- Participant has undergone renal transplantation.
- Participant has a condition or history of any illness that, in the opinion of the investigator, would have made the participant unsuitable for the study (e.g., may have confounded the results of the study or posed additional risk in administering the study therapy to the participant).
- Participant is considered unlikely to survive the 6-week study period or had a rapidly progressive illness, including septic shock, that was associated with a high risk of mortality.
- At the time of first study intervention administration, known presence of a cUTI caused by pathogens resistant to Cefepime - enmetazobactam.
- Presence of any of the following clinically significant laboratory abnormalities:
- Haematocrit <25% or haemoglobin <8 g/dL (<80 g/L, <4.9 mmol/L) for children ≥ 1 month, or <13 g/dL (<130 g/L, <8.0 mmol/L) for children < 1 month.
- Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST)>3 times the age-specific upper limit of normal (ULN), or total bilirubin >2 times ULN (except known Gilbert's disease) and Absolute Neutrophil count<1000/ mm3.
- eGFR <30 mL/min/1.73m2. (updated creatinine-based "Bedside Schwartz" equation (Schwartz et al. 2009))
- Participant has baseline QTcB (corrected Bazett's formula) of greater than 450 msec.
- History of seizures, excluding well-documented febrile seizures of childhood.
- If female, currently pregnant or breast feeding.
Trial locations and contacts
8 sites in 6 countries. Contact the study team or a site near you to ask about taking part.
8 sites in 6 countries
Czechia2 sites, 1 recruiting
- Withdrawn
Fakultní nemocnice Hradec Králové -Ústav klinické biochemie a diagnostiky
Hradec Králové, 500 05
- Recruiting
Oblastni nemocnice Kolin, a.s., nemocnice Stredoceskeho kraje - Detske oddeleni
Kolín, 280 02
Rene Hrdlicka, +420603964778, rene.hrdlicka@nemocnicekolin.cz
Hungary2 sites, 1 recruiting
- Withdrawn
Debreceni Egyetem Klinikai Központ Gyermekgyógyászati Klinika
Debrecen
- Recruiting
Kanizsai Dorottya Hospital
Nagykanizsa, 8800
Marta Nad, +36302042430, drnadmarta@gmail.com
Poland1 site, 1 recruiting
- Recruiting
SZPZOZ im. Dzieci Warszawy w Dziekanowie Leśnym
Łomianki
Joanna Samotyjek, 00 486 032 81617, joanna.samotyjek@szpitaldziekanow.pl
Slovakia1 site, 1 recruiting
- Recruiting
Národný ústav detských chorôb (NÚDCH)
Bratislava
Ludmila Podradska, +421903611441, podracka12@yahoo.com
About this study
Official title: Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI
This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.
Read the detailed description
The purpose of this study is to evaluate the blood concentrations and safety of the fixed dose combination of 2 drugs, cefepime with enmetazobactam administered intravenously in participants aged from birth to less than 18-years of age, hospitalised with a complicated urinary tract infection.
The treatment duration will be between 3 and 7 days, depending on the time needed for disappearance of signs and symptoms of the infection.
The participant will need to be hospitalised at least during the treatment administration period. After the last administration of cefepime and enmetazobactam, there will be the end of treatment visit (EOT), then 2 follow-up visits at 7 days (Test of Cure (TOC)), then 14 days (Late Follow-up (LFU)) after the end of treatment visit. The End of study Visit (EOS) will be conducted via telephone call (or a visit deemed necessary as per the investigator) 28 days after the EOT visit. The participants may be discharged from hospital at the discretion of the investigator after the end of treatment visit but will be required to return to the hospital for the 2 follow-up visits.
- Conditions
- Complicated Urinary Tract Infection
- Being tested
- cefepime and enmetazobactam combination
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cefepime and enmetazobactam combinationDrug
Also called cefepime-enmetazobactam
Cefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation
| Study group | Role | What they receive |
|---|---|---|
| cefepime and enmetazobactam unique study arm | Experimental | Each study participant will receive a two-hour intravenous administration of cefepime and enmetazobactam every 8 hours, as single drug in fixed dose combination (FDC) formulation at a ratio of 4 to 1. Receives: Drug: cefepime and enmetazobactam combination |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics Cmax
Maximum Plasma Concentration [Cmax] ; unit= mg/L
Measured: Day 1 - Day 2
Pharmacokinetics Tmax
Time to reach Cmax (Tmax) ; unit= h
Measured: Day 1 - Day 2
Pharmacokinetics AUC0-tau
Area under the plasma concentration time curve from time zero to the end of the dosing interval (AUC0-tau) ; unit= mg.h/L
Measured: Day 1 - Day 2
Pharmacokinetics AUC0-inf
Area under the concentration time curve from time zero extrapolated to infinity (AUC0-inf) ; unit= mg.h/L
Measured: Day 1 - Day 2
Pharmacokinetics t1/2
Elimination half-life (t1/2), apparent terminal elimination rate constant (λz) ; unit= h
Measured: Day 1 - Day 2
Pharmacokinetics CL & Vd
Clearance (CL, volume of plasma cleared of the drug per unit time) ; unit= L, Volume of distribution (Vd) ; unit= L
Measured: Day 1 - Day 2
Pharmacokinetics Cmin
Trough observed plasma concentration (Cmin) ; unit= mg/L
Measured: Day 1 - Day 2
Safety and Tolerability
Patients with treatment emergent adverse events (AE); unit=percentage
Measured: before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability
Patients with drug related related treatment emergent (AE); unit=percentage
Measured: before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability
Patients with study intervention discontinuation due to AE; unit=percentage
Measured: before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability
Patients with serious adverse event (SAE); unit=percentage
Measured: before 1st study intervention until EOT +28 Days (±5 Days)
Safety and Tolerability
Patients with drug related serious adverse event; unit=percentage
Measured: before 1st study intervention until EOT +28 Days (±5 Days)
Secondary outcomes (1)
Efficacy assessment
Efficacy Overall success rate (Combined clinical and microbiological success rate)
- Clinical response
- Microbiological response The main efficacy endpoint is the overall success rate (Combined clinical and microbiological success) in the m-MITT population at TOC.
The other efficacy endpoints are listed below:
- Clinical response of cure at TOC in m-MITT population
- Microbiological response of eradication at TOC in m-MITT population
- Overall success rate at Day 3, end-of-therapy (EOT), LFU in m-MITT population
- Clinical response rate at the Day 3, EOT, LFU visits in m-MITT population
- Microbiological response rate at the Day 3, EOT, LFU visits in m-MITT population
- Overall success rate at Day 3, EOT, TOC, LFU in Clinically Evaluable (CE) and in microbiologically evaluable (ME) populations
- Clinical response rate at Day 3, EOT, TOC, LFU in CE and ME populations
- Microbiological response at the Day 3, EOT, LFU visits in CE and ME populations
Measured: 7 Days (±2 Days) after the end-of-therapy (EOT)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2023
- Study start11 Sep 2023
- Primary completion21 May 2029 (estimated)
- Study completion21 May 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Complicated Urinary Tract InfectionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single Group Assignment
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Orchid Pharma Europe GmbH
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Innvocept Global Solutions Private Limited
- Responsible party
- Sponsor
- Investigators
- patrick velicitat, MD, Study director, Orchid Pharma Europe GmbH
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05826990
- Sponsor's protocol ID
- AT-202
- Status last verified
- Aug 2026
- First submitted
- 30 Jan 2023
- Last updated
- 20 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Single Group Phase 2 Study to Investigate Pharmacokinetics, Safety and Tolerability of Cefepime-Enmetazobactam Administered by IV Over 2 Hr in Male or Female Participants From Birth to Less Than 18 Years of Age Hospitalised With cUTI
- ClinicalTrials.gov ID
- NCT05826990
- Acronym / sponsor ID
- AT-202
- Conditions
- Complicated Urinary Tract Infection
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Orchid Pharma Europe GmbHIndustry (pharma, biotech, devices)
- Collaborators
- Innvocept Global Solutions Private Limited
- Study start
- 11 Sep 2023 (actual)
- Primary completion
- 21 May 2029 (estimated)
- Study completion
- 21 May 2029 (estimated)
- First posted
- 24 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This phase 2 study is part of regulatory commitments in the United States (PSP) and Europe (PIP) to evaluate cefepime-enmetazobactam in paediatric participants with cUTI to support extension of the indication for cefepime-enmetazobactam to children with cUTI.
Detailed description
The purpose of this study is to evaluate the blood concentrations and safety of the fixed dose combination of 2 drugs, cefepime with enmetazobactam administered intravenously in participants aged from birth to less than 18-years of age, hospitalised with a complicated urinary tract infection.
The treatment duration will be between 3 and 7 days, depending on the time needed for disappearance of signs and symptoms of the infection.
The participant will need to be hospitalised at least during the treatment administration period. After the last administration of cefepime and enmetazobactam, there will be the end of treatment visit (EOT), then 2 follow-up visits at 7 days (Test of Cure (TOC)), then 14 days (Late Follow-up (LFU)) after the end of treatment visit. The End of study Visit (EOS) will be conducted via telephone call (or a visit deemed necessary as per the investigator) 28 days after the EOT visit. The participants may be discharged from hospital at the discretion of the investigator after the end of treatment visit but will be required to return to the hospital for the 2 follow-up visits.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single Group Assignment
| Arm | Type | Receives |
|---|---|---|
| cefepime and enmetazobactam unique study arm | Experimental | Drug: cefepime and enmetazobactam combinationEach study participant will receive a two-hour intravenous administration of cefepime and enmetazobactam every 8 hours, as single drug in fixed dose combination (FDC) formulation at a ratio of 4 to 1. |
Who may qualify
- Ages
- Up to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
Key inclusion criteria (39 listed)
- Participant must be from birth to <18 years of age. Participants up to 2 months must have been born at term or preterm with a gestational age ≥32 weeks.
- Written informed consent from parent(s) or other legally acceptable representative(s), and informed assent from participant (if age appropriate according to local regulations).
- If female and has reached menarche, or has reached Tanner stage 3 development, (even if not having reached menarche) the participant is authorized to participate in this clinical study if the following criteria are met:
- Participant has a clinically suspected and/or bacteriologically documented complicated urinary tract infection (cUTI) or acute pyelonephritis judged by the investigator to require the participant to be hospitalized for treatment with intravenous (i.v.) therapy.
- The causative pathogen is confirmed or suspected to be susceptible to cefepime-enmetazobactam.
Key exclusion criteria (21 listed)
- History of serious allergy, hypersensitivity (e.g., anaphylaxis), or any serious reaction to cefepime, any cephalosporin, penicillins, β-lactamase inhibitors (e.g., tazobactam, sulbactam, or clavulanic acid), or other β-lactam agents.
- Previous enrolment in this study, or in another interventional study ≤30 days before i.v. administration of study intervention.
- Concurrent infection requiring systemic antibiotics in addition to the i.v. study intervention therapy at the time of first study intervention administration.
- Receipt of systemic antibiotics within 24 hours before obtaining the study qualifying pre-treatment baseline urine sample and before study intervention therapy. Exceptions are:
- Receipt up to 24 hours of short-acting antibacterial agent with a daily dose not completed. (Refer protocol ► Section 10.5, Appendix 5 for the list of allowed and disallowed antibiotics).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| cefepime and enmetazobactam combinationAlso: cefepime-enmetazobactamCefepime and enmetazobactam fixed dose combination administered intravenously every 8 hours as single drug formulation | Drug | cefepime and enmetazobactam unique study arm |
Primary outcome
Pharmacokinetics Cmax
Time frame: Day 1 - Day 2
Maximum Plasma Concentration [Cmax] ; unit= mg/L
Pharmacokinetics Tmax
Time frame: Day 1 - Day 2
Time to reach Cmax (Tmax) ; unit= h
Pharmacokinetics AUC0-tau
Time frame: Day 1 - Day 2
Area under the plasma concentration time curve from time zero to the end of the dosing interval (AUC0-tau) ; unit= mg.h/L
Pharmacokinetics AUC0-inf
Time frame: Day 1 - Day 2
Area under the concentration time curve from time zero extrapolated to infinity (AUC0-inf) ; unit= mg.h/L
Pharmacokinetics t1/2
Time frame: Day 1 - Day 2
Elimination half-life (t1/2), apparent terminal elimination rate constant (λz) ; unit= h
Pharmacokinetics CL & Vd
Time frame: Day 1 - Day 2
Clearance (CL, volume of plasma cleared of the drug per unit time) ; unit= L, Volume of distribution (Vd) ; unit= L
Pharmacokinetics Cmin
Time frame: Day 1 - Day 2
Trough observed plasma concentration (Cmin) ; unit= mg/L
Safety and Tolerability
Time frame: before 1st study intervention until EOT +28 Days (±5 Days)
Patients with treatment emergent adverse events (AE); unit=percentage
Safety and Tolerability
Time frame: before 1st study intervention until EOT +28 Days (±5 Days)
Patients with drug related related treatment emergent (AE); unit=percentage
Safety and Tolerability
Time frame: before 1st study intervention until EOT +28 Days (±5 Days)
Patients with study intervention discontinuation due to AE; unit=percentage
Safety and Tolerability
Time frame: before 1st study intervention until EOT +28 Days (±5 Days)
Patients with serious adverse event (SAE); unit=percentage
Safety and Tolerability
Time frame: before 1st study intervention until EOT +28 Days (±5 Days)
Patients with drug related serious adverse event; unit=percentage
1 secondary outcome
Efficacy assessment
Time frame: 7 Days (±2 Days) after the end-of-therapy (EOT)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Complicated Urinary Tract Infection
Active, not recruitingObservational study
Clinical Performance Evaluation of the QIAstat-Dx® cUTI Plus AMR
Complicated Urinary Tract Infection
RecruitingPhase 4
Single Dose Intravenous Antibiotics for Complicated Urinary Tract Infections in Children
Complicated Urinary Tract Infection, Infection
RecruitingPhase 2
A Study to Assess How Vaborem® is Taking up in the Body and Tolerated in Paediatric Patients With Gram Negative Infections, Including But Not Restricted to Complicated Urinary Tract Infections
Gram Negative Infections
Not yet recruitingPhase 2
This is a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Hospitalized Adult Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis
Complicated Urinary Tract Infections(cUTI), Acute Pyelonephritis
Active, not recruitingPhase 2
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Meropenem-Vaborbactam in Children With Complicated Urinary Tract Infection, Including Acute Pyelonephritis
Acute Pyelonephritis, Complicated Urinary Tract Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
patrick velicitat, MD study director
Orchid Pharma Europe GmbH
8 sites in 6 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing cefepime and enmetazobactam combination in people with Complicated Urinary Tract Infection, run by Orchid Pharma Europe GmbH at 8 sites in 6 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 39 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Czechia, Hungary, France, Poland, Slovakia and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact patrick velicitat, MD (+33781144026, patrickv@orchidpharma.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics Cmax (time frame: Day 1 - Day 2). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026.